Xolair: Roche announces positive results from phase III OUtMATCH study of Xolair for the treatment of one or more food allergies
Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)─sponsored phase III OUtMATCH study, which provide further evidence supporting the role of Xolair
Read full article »
CEO
XOLAIR offers treatment for moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria in appropriate patients.
Read more